Liminatus Pharma, Inc. - Class A Common Stock (LIMN)
6.6000
+0.8200 (14.19%)
NASDAQ · Last Trade: Jul 23rd, 12:37 PM EDT
Detailed Quote
Previous Close | 5.780 |
---|---|
Open | 6.540 |
Bid | 6.600 |
Ask | 6.700 |
Day's Range | 6.230 - 7.190 |
52 Week Range | 4.400 - 33.66 |
Volume | 572,695 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 392,842 |
Chart
News & Press Releases
Preclinical-stage biotech company explores digital asset treasury opportunities to enhance capital efficiency while maintaining core focus on immunotherapy innovation
By Liminatus Pharma Inc. · Via GlobeNewswire · July 22, 2025
Via Benzinga · July 17, 2025
Via Benzinga · July 10, 2025
Via Benzinga · July 9, 2025
Via Benzinga · July 3, 2025
U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices were trading slightly higher.
Via Benzinga · July 2, 2025
Via Benzinga · June 30, 2025
Via Benzinga · June 26, 2025
Via Benzinga · June 25, 2025
Via Benzinga · June 25, 2025
Via Benzinga · June 25, 2025
Via Benzinga · June 24, 2025
Via Benzinga · June 24, 2025
Via Benzinga · June 20, 2025
Via Benzinga · June 18, 2025
Via Benzinga · June 17, 2025
Via Benzinga · June 13, 2025
Via Benzinga · June 13, 2025
Via Benzinga · June 12, 2025
Via Benzinga · June 12, 2025
Via Benzinga · June 12, 2025